Appili Therapeutics Inc. (OTCMKTS:APLIF) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 106,800 shares, a decrease of 53.2% from the December 15th total of 228,000 shares. Based on an average daily volume of 67,500 shares, the days-to-cover ratio is currently 1.6 days.
Shares of APLIF opened at $0.09 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 0.78 and a quick ratio of 0.78. The company’s fifty day moving average is $0.14 and its two-hundred day moving average is $0.46. Appili Therapeutics has a 1 year low of $0.07 and a 1 year high of $1.30.
Appili Therapeutics (OTCMKTS:APLIF) last announced its quarterly earnings data on Friday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Appili Therapeutics had a negative net margin of 40,158.18% and a negative return on equity of 361.19%. On average, sell-side analysts predict that Appili Therapeutics will post -0.36 earnings per share for the current year.
Appili Therapeutics Company Profile
Appili Therapeutics Inc, a biopharmaceutical company, acquires, develops, and commercializes novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1501, a taste-masked oral liquid suspension formulation of an antibiotic, metronidazole; ATI-1503 that develops a class of gram-negative targeting antibiotics; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis.
Featured Story: What does it mean to hold a stock in street name?
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.